Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
Andreas Hochhaus(Jena University Hospital), H. Kantarjian(The University of Texas MD Anderson Cancer Center), Michael W. Deininger(Versiti Blood Center of Wisconsin), Jeffrey H. Lipton(Princess Margaret Cancer Centre), Athena Countouriotis(Bristol-Myers Squibb (Germany)), Francisco Cervantes(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Sélim Corm, Richard T. Silver(Cornell University), Dietger Niederwieser(Leipzig University of Applied Sciences), Michele Baccarani(University of Bologna), Stuart L. Goldberg(Hackensack University Medical Center), Timothy P. Hughes(Royal Adelaide Hospital), Rana Ezzeddine(Institut Claudius Regaud), Richard M. Stone(Dana-Farber Cancer Institute), Richard A. Larson(Urbana University), Jane F. Apperley(Hammersmith Hospital), Martin C. Müller(Universität Hamburg), Hervé Dombret(Université Paris Cité), Neil P. Shah(Unknown), Lydia Roy(Centre Hospitalier Universitaire de Poitiers)
Cited by 354
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k